Literature DB >> 20454843

Risk of second primary malignancies following nasopharyngeal carcinoma in Hong Kong.

William B Goggins1, Ignatius T S Yu, Lap Ah Tse, Sing Fai Leung, Stewart Y Tung, Kai Sing Yu.   

Abstract

Nasopharyngeal carcinoma (NPC) is rare in most of the world but common among southeast Asians. Since NPC is usually diagnosed at relatively young ages and most patients now survive, the issue of second primary tumors (SPTs) has become important. Previous studies of SPTs among NPC survivors have given conflicting results. Data on patients with NPC diagnosed between 1996 and 2002 were abstracted from the medical records of two Hong Kong oncology centers. SPT incidence in these patients was compared to that of Hong Kong's general population using standardized incidence ratios (SIR). Eight-four patients were observed to have at least 1 SPT and 92 total additional cancers (SIR = 1.93, 95% CI = 1.55-2.37). The excess risk was greater for women and patients under 40 at diagnosis. Significant excesses were found for tongue, lung, nasal and middle ear, and brain cancers. The pattern of sites at which the greatest excess risk occurred is consistent with the hypothesis that much of the excess is due to treatment effects. The greater excess risk among patients diagnosed before 40 points to possible genetic influences. More research is needed to determine the reasons for greater excess risk among women.

Entities:  

Mesh:

Year:  2010        PMID: 20454843     DOI: 10.1007/s10552-010-9574-x

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  2 in total

1.  Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

Authors:  Fen Xue; Xiaoshuang Niu; Chaosu Hu; Xiayun He
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

2.  Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma.

Authors:  Mian Xi; Shi-Liang Liu; Lei Zhao; Jing-Xian Shen; Li Zhang; Peng Zhang; Meng-Zhong Liu
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.